

## **Epidemiology of chronic pancreatitis: burden of the disease and consequences**

Philippe Lévy, Enrique Domínguez-Muñoz, Clem Imrie, Matthias Löhr and Patrick Maisonneuve  
*United European Gastroenterology Journal* 2014 2: 345 originally published online 18 August 2014  
DOI: 10.1177/2050640614548208

The online version of this article can be found at:  
<http://ueg.sagepub.com/content/2/5/345>

---

Published by:



<http://www.sagepublications.com>

On behalf of:

United European Gastroenterology



Additional services and information for *United European Gastroenterology Journal* can be found at:

**Email Alerts:** <http://ueg.sagepub.com/cgi/alerts>

**Subscriptions:** <http://ueg.sagepub.com/subscriptions>

**Reprints:** <http://www.sagepub.com/journalsReprints.nav>

**Permissions:** <http://www.sagepub.com/journalsPermissions.nav>

>> [Version of Record](#) - Sep 22, 2014

[OnlineFirst Version of Record](#) - Aug 18, 2014

[What is This?](#)



# Epidemiology of chronic pancreatitis: burden of the disease and consequences

Philippe Lévy<sup>1</sup>, Enrique Domínguez-Muñoz<sup>2</sup>, Clem Imrie<sup>3</sup>, Matthias Löhr<sup>4</sup> and Patrick Maisonneuve<sup>5</sup>

## Abstract

The epidemiology of chronic pancreatitis (CP) is incompletely understood. A number of difficulties exist in estimating the prevalence and incidence of CP. Long-term follow-up is often problematic, especially in chronic alcoholics, and obtaining a formal and standardised diagnosis can take years. The available studies are reasonably consistent in their estimation of the incidence of CP but few studies have attempted to estimate prevalence. Although life expectancy in CP is diminished compared with control populations, median survival lies in the range of 15–20 years. Such a survival would suggest a prevalence of CP rather higher than that determined from the survey studies. A recent epidemiological study in France found an annual incidence of 7.8 per 100,000. Assuming a survival of 15–20 years, the annual prevalence should be between 120 to 143 per 100,000. Overall, our understanding of the epidemiology of CP is poor compared with other illnesses. We consider that both prevalence and the rate of pancreatic insufficiency and of CP are currently underestimated. There is a distinct need for more studies to remedy this lack of knowledge.

## Keywords

Chronic pancreatitis, epidemiology, pancreatic exocrine insufficiency

Received: 6 June 2014; accepted: 23 July 2014

## Introduction

Chronic pancreatitis (CP) is a serious disorder which can have a severe impact on quality of life<sup>1</sup> in addition to life-threatening long-term sequelae.<sup>2,3</sup> As well as pain, pancreatic exocrine insufficiency can result in malnutrition (in a population apt to neglect their nutrition). Longer-term complications include diabetes mellitus and pancreatic cancer.<sup>2,3</sup>

While understanding of this illness is improving, there are a number of aspects where knowledge is lacking. In particular, the epidemiology of CP is far from perfectly described. Difficulty in the formal diagnosis that requires long-term follow-up (a time necessary for the development of ductal abnormalities or pancreatic calcifications), and high variability in severity of the illness and evolution profile directly impact the quality of epidemiological studies that are scarce and limited.

While many patients with CP enter the health care system via a gastroenterologist or surgeon due to an acute manifestation such as pancreatitis or pain, much

of their long-term care is conducted in the community by general practitioners or diabetologists and is consequently less visible to epidemiological studies performed in the gastroenterological milieu. However, studies in which the incidence of CP is estimated from the number of cases presenting to gastroenterologists or surgeons make the assumption that acute pancreatitis or onset of chronic abdominal pain are always early manifestations of CP, an assumption which is in part false.

<sup>1</sup>Service de Pancréatologie-Gastroentérologie, Pôle des Maladies de l'Appareil Digestif, DHU UNITY, Hôpital Beaujon, Faculté Denis Diderot, Clichy Cedex, France

<sup>2</sup>University Hospital of Santiago de Compostela, Spain

<sup>3</sup>University of Glasgow, Glasgow, United Kingdom

<sup>4</sup>Karolinska University Hospital & Karolinska Institutet, Stockholm, Sweden

<sup>5</sup>European Institute of Oncology, Milan, Italy

### Corresponding author:

Philippe Lévy Service de Pancréatologie-Gastroentérologie, Pôle des Maladies de l'Appareil Digestif, DHU UNITY, Hôpital Beaujon, Faculté Denis Diderot, APHP, 92118 Clichy Cedex, France.

Email: philippe.levy@bjn.aphp.fr

Most cases of CP are associated with heavy alcohol intake and cigarette smoking, and the associated stigma makes longitudinal follow-up of these non-compliant patients by the same physician difficult to accomplish. Thus, the incidence of CP is easier to estimate than is its prevalence.

In the context of this imperfect understanding of the epidemiology, and particularly of the prevalence of CP, the objective of the present review is to assess the current state of knowledge of the epidemiology of CP and of pancreatic exocrine insufficiency.

### Problems in the diagnosis of chronic pancreatitis

The problems encountered by epidemiological studies are further compounded by the difficulty in rigorously diagnosing CP. No simple and reliable diagnostic test exists for early CP, and definitive diagnosis can take years to obtain.

Because histology is usually not available, the diagnosis of CP is primarily based on the demonstration of pancreatic ductal or parenchymal morphological and/or functional changes that typically develop over time in the course of the disease.<sup>4</sup> Diagnosis of CP is thus mainly based on imaging procedures (magnetic resonance cholangiopancreatography (MRCP), computed tomography (CT) scan, endoscopic ultrasound (EUS)). Functional testing of the exocrine secretion in this context may be of help in cases with inconclusive morphological findings, but this is rarely used in clinical

practice since values are often in the normal range, at least at the beginning of the disease. Functional testing gives positive results only when endocrine or exocrine secretory capacities are largely decreased, which is late in the course of the disease.<sup>5</sup>

Due to gas interposition and a low sensitivity for detecting mild to moderate changes in the disease, abdominal ultrasound is far from an appropriate method for the diagnosis of this illness in clinical practice.<sup>6</sup> This method, widely used for the diagnostic workup of patients with abdominal pain, will consequently miss the majority of patients with CP except those with advanced disease. While CT is an accurate method for detecting pancreatic calcifications and main duct dilation, it is not effective for earlier pancreatic changes such as mild parenchymal changes due to fibrosis.<sup>6</sup>

MRCP, with or without secretin-induced stimulation of pancreatic secretion, associated with diffusion-weighted magnetic resonance imaging (MRI) or contrast (gadolinium)-enhanced MRI allows accurate evaluation of pancreatic ductal and parenchymal changes, together with a semi-quantitative evaluation of the pancreatic exocrine secretion.<sup>7,8</sup> MRCP and MRI are therefore useful methods for the diagnosis of CP.

EUS is currently considered as the most accurate method for diagnosing CP as it demonstrates the presence and severity of pancreatic parenchymal and ductal changes with a high degree of accuracy (Table 1),<sup>9–11</sup> The presence of five or more EUS criteria offers a high

**Table 1.** Endoscopic ultrasound criteria of chronic pancreatitis (Modified from Catalano et al.<sup>12</sup>)

Features	Definition
<b>Parenchymal features</b>	
Hyperechoic foci with shadowing	Echogenic structures $\geq 2$ mm in length and width that shadow
Lobularity with honeycombing	Well-circumscribed, $\geq 5$ mm structures with enhancing rims and relatively echo-poor centres, with $\geq 3$ contiguous lobules
Lobularity without honeycombing	Well-circumscribed, $\geq 5$ mm structures with enhancing rims and relatively echo-poor centres, with noncontiguous lobules
Hyperechoic foci without shadowing	Echogenic structures $\geq 2$ mm in length and width with no shadowing
Cysts	Anechoic, rounded/elliptical structures with or without septations
Stranding	Hyperechoic lines of $\geq 3$ mm in length in at least two different directions with respect to the imaged plane
<b>Ductal features</b>	
MPD calculi	Echogenic structures within the MPD with acoustic shadowing
Irregularity of MPD contour	Uneven or irregular outline and ectatic course
Dilated side branches	3 or more tubular anechoic structures each measuring $\geq 1$ mm in width, budding from the main pancreatic duct
Main pancreatic duct dilation	$\geq 3.5$ mm in body or $> 1.5$ mm in tail
Hyperechoic duct margin	Echogenic, distinct structure greater than 50% of the entire MPD in the body and tail

probability of a CP diagnosis, whereas the diagnosis is unlikely in patients with none to two EUS criteria. Patients with three or four EUS criteria of CP are in a grey zone where the disease can be over-diagnosed.<sup>9–11</sup> Nevertheless, most of these patients with 3–4 EUS criteria will actually have CP if a compatible clinical picture is present. EUS evaluation is, however, subjective, and there is a lack of standardisation in terms of the technique, nomenclature, and quantitative criteria used for CP.<sup>12,13</sup> EUS needs general anaesthesia or deep sedation and is a rather invasive method that, while it can be repeated, is not appropriate for routine use.

Based on the scenario described above, it is easy to understand that the diagnosis of CP in clinical practice is a far from simple task. In practice, most cases of CP are identified from their clinical context (e.g. recurrent acute pancreatitis in heavy alcoholics) and confirmed several years later by abnormal duct imaging or the occurrence of pancreatic calcifications. Diagnosis of CP is even more difficult in the context of epidemiological studies, where simple, accurate and non-invasive tests are required. These considerations strongly suggest that CP is an under-diagnosed disease. In this context, clinical guidelines for the diagnosis and treatment are clearly required; some have been initiated or are in development in several countries.<sup>14–18</sup>

### Epidemiology of chronic pancreatitis

While incidence provides information on the risk of developing a disease within a specified period of time, prevalence provides information on how widespread the disease is in the population. When the incidence is about constant over time, prevalence can be estimated as the product of disease incidence and average disease duration, typically the median life expectancy in cases of chronic disease. Incidence is generally easier to ascertain, especially in diseases starting on an acute mode, than prevalence as it relies on first manifestations. Depending on the disease, the diagnosis can be accurately obtained from medical, radiological, surgical or pathological departments.

Estimates of the prevalence of a chronic disease might be obtained from different sources if available such as national or regional registries (e.g. cystic fibrosis registries), population or hospital surveys, hospital discharge data or, in the absence of a direct measure, could be estimated using mathematical models based on available incidence and survival data.

Only scarce data are available on the prevalence and incidence of CP, while few reports on the long-term outcome and survival of selected series of patients with CP have been published.

The reported incidence rates are grossly in the same ranges (summarised in Table 2), varying from 4/100,000 in the UK<sup>19</sup> and US<sup>20</sup> to 13.4/100,000 in Finland,<sup>21</sup> with intermediate incidence rates reported for Denmark (10),<sup>22</sup> Poland (5.0),<sup>23</sup> Germany (6.4),<sup>24</sup> the Czech Republic (7.8),<sup>25</sup> and France (7.7).<sup>26</sup> There is a trend for the most recent studies to show a higher incidence of CP. Since alcohol consumption and smoking levels are stable or declining in many of the countries where studies have been conducted, the differences likely reflect changes in methodology or better diagnostic tools rather than absolute changes in incidence of CP.

Some studies suggest that the role of alcohol as an aetiological factor may be less marked in, for example, Japanese or American populations, than it is in European populations.<sup>27</sup> Other studies emphasise the role of smoking, not only as a significant aetiological co-factor in CP,<sup>28–31</sup> but also as a habit that accelerates the evolution and increases the mortality of CP.<sup>32</sup>

Certain trends are common to all the studies: there is a significant gender difference; men have a higher incidence of CP than women, at least twice as high. There is a trend for the most recent studies to show a higher incidence of CP. In the study of Jaakkola et al. in Finland, for example, incidence increased by 26% between 1977 and 1989. A study in China showed a marked increase in the prevalence of CP between 1996 and 2003 (from 3.08/100,000 to 13.52/100,000). It is noteworthy in this study that, in contrast to other studies from the Asia-Pacific regions, the majority of cases were among middle-aged patients and that the areas most affected by the increase were in the most westernised part of China.<sup>33</sup> Given this historical trend towards increasing incidence of CP and the lack of recent epidemiological studies, it is likely that the literature (as represented in Table 2) underestimates the current true rate of CP. In those studies where alcohol consumption was measured, a correlation between the increase in alcohol consumption and CP was a universal finding.<sup>21</sup> However, most of these studies were done in a period of generally rising alcohol consumption. In many countries in Europe, alcohol consumption has ceased to rise, (or has even begun to fall somewhat, particularly in southern Europe) but remains relatively high compared with the rest of the world.<sup>34</sup>

The most recent epidemiological study (2006) in Europe in CP was conducted by one of the authors of this review (Lévy et al.).<sup>26</sup> This study recruited a significant fraction of all gastroenterologists in France and was methodologically rigorous. It was a cross-sectional epidemiological study that examined both the prevalence and incidence of CP. French gastroenterologists were asked to report the number of consultations

Table 2. Incidence of chronic pancreatitis

Reference	Incidence/ 100,000	Prevalence/ 100,000	Year of study	Country	Patients	Notes
Andersen et al., 1982 <sup>22</sup>	6.9		1970-1975	Denmark	Retrospective study of chronic pancreatitis diagnoses	
	10.0		1975-1979		Hospital survey	
Dziedziszewski et al., 1990 <sup>23</sup>	5.0	17	1982-1987	Poland		
Johnson and Hosking, 1991 <sup>19</sup>	4.3 (M) 2.1 (F)		1960-1984	UK	Hospital discharge records	Four-fold increase in discharges for men and two-fold increase in women paralleled by increases in alcohol consumption in the same period
Jaakkola and Nordback, 1993 <sup>21</sup>	13.4		1989	Finland	Global survey from discharge records	Incidence of discharge for chronic pancreatitis paralleled alcohol consumption
Díte et al., 2001 <sup>25</sup>	7.9		1999	Czech Republic	New cases registered among a population of 1.3 million	65% of patients with alcohol consumption greater than 75 g/day
Lankish et al., 2002 <sup>24</sup>	6.4		1988-1995	Germany	Review of patient records from single hospital	
Lévy et al., 2006 <sup>26</sup>	7.7	26.4	2003	France	Survey among gastroenterologists	
Hirota et al., 2007 <sup>36</sup>	11.9	36.9	2007	Japan	Survey of relevant hospital departments	
Wang et al., 2009 <sup>33</sup>		3.08 13.52	1996 2003	China	Survey of hospital records	
Yadav et al., 2011 <sup>20</sup>	4.05	41.76	1997-2006	USA	Hospital record survey and clinical review	
Garg and Tandon, 2004 <sup>54</sup>	114-200			India	Survey in experts	

undertaken for CP during a 3-month period and the number of new cases diagnosed during the same period.

A notable feature of this study was the apparent discrepancy between the incidence and prevalence of CP. This study estimated the prevalence at 15,830 cases and the incidence at 4646 per year (crude annual incidence: 7.8/100,000). Using the accepted epidemiological formula, these results would imply duration of illness of around 3.4 years. An older study in Poland (in a hospital setting) determined both incidence and prevalence and, while both were lower than in the recent study in France, the ratio of prevalence to incidence suggests a duration of illness of less than 4 years, which is also far from clinical experience.<sup>23</sup>

This discrepancy needs explanation. CP patients typically attend, or are referred to, a gastroenterologist or a surgeon for their first bouts of illness as it has a more acute presentation (including acute pancreatitis and abdominal pain) than later (where pain is not usually a feature, or is at least masked by treatments and acute pancreatitis is rarer). After 5 or 10 years of chronic illness, the main problems encountered are pancreatic exocrine insufficiency and diabetes mellitus, and such long-term care is normally in the hands of a general practitioner or diabetologist. Quantifying the number of patients being followed by general practitioners/diabetologists and no more by gastrointestinal specialists is difficult, but can be crudely approximated from the preliminary study by Lévy et al.: 41% of the general practitioners in the preliminary survey declared they saw at least one patient with CP on a regular basis in the last year, with a mean of 2.7 patients. Given there are approximately 56,000 general practitioners in France, this implies that 24,000 of them saw at least one patient, an average of around 65,000 CP patients. Some 30% of these patients (around 20,000) were not under the simultaneous care of a gastroenterologist and therefore invisible in the prevalence calculations of this study. A similar calculation applied to the patients under the care of diabetologists yields approximately a further 2500 patients invisible to surveys of gastroenterologists as a whole. These figures provide a prevalence estimate that is much more consistent with the incidence data collected by Lévy et al. Using the incidence figure of 4646 (from this study with a more reasonable life expectancy figure of 20 years (see following discussion)), implies a prevalence of CP of 92,920 patients in France. This figure can be considered an outer limit of the number of CP patients, since their life expectancy is known to be somewhat impaired compared with the population as a whole.<sup>35</sup>

This conclusion is confirmed by another recent epidemiological study performed in Japan in 2007.<sup>36</sup> A large survey of 3027 hospital departments resulted in 1100 responses describing 6339 patients treated and

2217 new patients during the 1-year index period. The estimated incidence and prevalence were 11.9 and 36.9 per 100,000. Although comparing the incidence and prevalence of CP across populations with significant genetic and cultural differences is fraught with difficulty, it is noteworthy that the duration of illness implied in the Japanese study is very similar to that in the French study (3.1 vs. 3.4 years, respectively), and so far from clinical and investigational experience.

A recent study of the incidence and prevalence of CP in Olmstead County, USA, made use of unusual arrangements for the provision of medical care in its methodology.<sup>20</sup> In this US county, nearly all medical care is provided by a central hospital (renowned for keeping large longitudinal databases of patient records) and a single primary care centre. This permits more complete capture of epidemiological data than it is possible in the gastroenterologist-gatekeeper scenario. Interestingly, this study provided estimates of incidence (4.05/100,000) and prevalence (41.8/100,000), more in line with longevity estimates for patients with CP.

### Natural history of chronic pancreatitis

CP is an illness whose natural history can be grossly divided into three phases with huge overlap.

- **Early phase:** approximately the first 5 years of the illness are characterised by acute pancreatitis, pain, hospitalisations and surgical interventions.
- **Middle phase:** lasting 5–10 years in which acute manifestations are reduced, but stricture of the main biliary duct, chronic pseudocysts and other morphological changes such as duct strictures and pancreatic calcifications become apparent. Pancreatic insufficiencies progressively appear.
- **Late phase:** from approximately 10 years onwards, acute manifestations become rare and the focus should be put on diabetes mellitus and pancreatic exocrine insufficiency.

The progression and duration of these phases are highly dependent on the causative factors and vary from one patient to another. Further, the sequence of events is not canonical, i.e. the various symptoms (pain, calcifications/stones, diabetes mellitus, exocrine insufficiency) can occur in all possible sequences.<sup>37</sup> The rate and severity of progression are influenced by the continuation or otherwise of alcohol and tobacco usage.<sup>38</sup> Smoking is currently proposed to be the driving force behind the progression of pancreatitis. Fibrosis, which progresses as a consequence of a repeated inflammatory response, develops, with a corresponding reduction in exocrine and endocrine tissues.<sup>39</sup>

The relevance of the natural history of CP has two important implications for epidemiological studies. Gastroenterologists are most likely to become involved in the care of patients with CP during the early phase of the disease, in which pain and surgical interventions are principle features of the illness. Thus, surveys of gastroenterologists can yield useful incidence data, since the gastroenterologist acts as a gatekeeper through whom many patients with acute manifestations pass. However, the gatekeeper role of the gastroenterologist might be bypassed in those patients whose illness does not follow the 'classical' course, or in whom disease is already advanced and does not need digestive specialist care. Such patients would not be visible to surveys of gastroenterologists.

### Duration of disease in chronic pancreatitis

In common with the epidemiology, studies on the long-term survival of patients with CP are scarce and recent data scarcer still; only a single study includes data from patients treated after the turn of the century. The available data are summarised in Table 3. In 1984, Ammann et al.<sup>40</sup> reported on 245 patients with CP (163 with alcoholic relapsing pancreatitis). The median survival time in alcoholic CP was 20–24 years after disease onset. Lowenfels et al.<sup>28</sup> evaluated survival of 2015 patients with CP as part of an international multicentre study (Switzerland, Germany, USA, Italy, Sweden, Denmark). In all, 559 deaths were observed. Overall survival at 10 years was 70% and 45% at 20 years. Cavallini et al.<sup>41</sup> followed 715 patients with CP seen at the university of Verona, Italy, for a median follow-up of 10 years. The mean age at onset of disease was 41 years. The 5-, 10-, 15- and 20-year mortality rate was, respectively, 3%, 13.7%, 25.7% and 37%. Most of these patients were also included in the Lowenfels study. Thuluvath et al.,<sup>42</sup> in a retrospective study,

studied 193 consecutive patients admitted to the Johns Hopkins Hospital, USA, for the control of pain or a complication of CP. Long-term follow-up (mean 10 years) was available for 107 patients. The 5-, 10- and 15-year mortality rate was, respectively, 14%, 18%, and 20%. Schnelldorfer et al.<sup>43</sup> followed 229 patients who underwent surgery for CP at the Medical University of South Carolina, USA. One-year, 3-year, and 5-year survival was 97%, 87%, and 82%, respectively. Pedrazzoli et al.<sup>35</sup> followed 170 patients (95% were smokers) who underwent and survived surgery for CP in Padova, Italy, for a median duration of 15.5 years. Death rate after 5, 10, 15, 20, 25 and 30 years was 15.3, 34.4, 48.4, 62.0, 71.9 and 76.5. The median survival was 15.5 years (95% CI = 13.3–18.5). A smaller study (82 patients) by Seican and colleagues found a higher death rate of 17% during a relatively short follow-up of 25 ± 17 months.<sup>44</sup>

In all these studies, it is noteworthy that the majority of death (60–75%) is due to extrapancreatic consequences of alcohol and smoking over use (e.g. lung or oesophageal cancer, liver cirrhosis, heart attack) rather than CP by itself.

Only a single study has compared the mortality of CP with that of the population as a whole; a study in France compared the mortality and causes of mortality in 240 CP patients with that of matched control group from the general population. The mean age at onset of CP was 41.5 years and the mean age at death for the 57 patients who died during 8.7 years of follow-up was 52.3 years. The excess mortality compared with a matched French population was 35.8% over a 20-year course of illness.<sup>45</sup>

From these reports (summarised in Table 3), it emerges that the median survival of CP patients is between 15 and 20 years from onset, and moreover, diagnosis is often delayed for several years from the start of the disease. In the studies by Thuluvath

**Table 3.** Long-term survival of patients with chronic pancreatitis

Reference	N Patients	Mean age (years)	Enrolment Period	Death rate %						Median survival
				5-year	10-year	15-year	20-year	25-year	30-year	
Ammann et al., 1984 <sup>40</sup>	245									20–24 years in alcoholic chronic pancreatitis
Levy et al., 1989 <sup>45</sup>	240	41.5	Assessed 1987				35.8			
Lowenfels et al., 1994 <sup>28</sup>	2015	46	1946–92	15.0	30.0	45.0	55.0			
Cavallini et al., 1998 <sup>41</sup>	715	41	1971–95	3.0	13.7	25.7	37.0			
Thuluvath et al., 2003 <sup>42</sup>	107	–	1979–89	14.0	18.0	20.0				
Schnelldorfer et al., 2007 <sup>43</sup>	229	46	1995–2003	18.0	25.0					
Pedrazzoli et al., 2008 <sup>35</sup>	170	45	1970–99	15.3	34.4	48.4	62.0	71.9	76.5	15.5 years

et al.<sup>42</sup> and Schnelldorfer et al.,<sup>43</sup> for which follow-up was shorter, 82% and 75% of patients, respectively, were still alive after 10 years. We should keep in mind that the majority of patients with CP are heavy smokers, and are therefore exposed to the additional hazard of smoking. As a long-term follow-up of 34,439 male British doctors<sup>46</sup> demonstrated, on average, cigarette smokers die about 10 years younger than non-smokers, so we should expect that the life expectancy of patients with CP should be at least 10 years shorter than that of the general population. In the context of the most recent epidemiological data,<sup>26</sup> life expectancy at age 51 (median age of patients in this study) in France is 29.18 years for men and 34.92 for women (INED)<sup>47</sup>. Thus, the life expectancy of patients with CP, for whom smoking is a major determinant of death,<sup>28</sup> is likely to be diminished significantly compared with the population at large. Clinical wisdom suggests a median survival in the range 15–20 years.

### Pancreatic exocrine insufficiency

A large subset of patients with CP will suffer from pancreatic exocrine insufficiency and consequent malnourishment due to impaired digestion of nutrients, in particular fats, micronutrients and proteins. Although a proportion of patients present initially with abnormal pancreatic exocrine function, it is commonly associated with several years of evolution. Pancreatic function tests have therefore been used over decades for the diagnosis of the disease.<sup>5</sup> With this aim, only the secretin-pancreozymin test and the endoscopic test are sensitive enough. These tests are both invasive and cumbersome for routine use in clinical practice. The use of other functional tests such as the quantification of the coefficient of fat absorption and the <sup>13</sup>C-mixed triglyceride breath test are limited to just a few teams.<sup>5,48</sup> Measurement of faecal fat output is complex, requires complete stool collection over at least 2 days and a lipid-rich diet for 4–5 days. In daily practice, it is very rarely performed nowadays. Faecal elastase is useful for detecting moderate to severe reduction of pancreatic secretion in patients with CP.<sup>5,49</sup> This test has the advantages of being simple, non-invasive and easily applicable to routine clinical application, but sensitivity for the diagnosis of patients with non-advanced CP is limited. Other tests used in the past (e.g. Lundh test, N-benzoyl-tryosyl para-aminobenzoic acid test, pancreolauryl test, amino acid consumption test) are often no longer available for clinical practice.

A comprehensive meta-analysis of non-invasive pancreatic function tests concluded that none of the available methods possessed sufficient validity to diagnose mild to moderate pancreatic exocrine insufficiency.<sup>50</sup>

However, the assessment of pancreatic exocrine insufficiency is difficult to accomplish. Clinical diagnosis is possible, but unreliable.<sup>51</sup> The rate of pancreatic exocrine insufficiency in patients with CP is not well studied and where it has been studied, there is considerable variation between studies depending mostly on the duration of the diseases in selected patients (Table 4). The dearth of reliable information in this area is due partly to the lack of easily applied clinical tests and partly to the steep rise in the proportion of CP patients with pancreatic exocrine insufficiency as the disease progresses. A study of 155 patients with CP in a medical rehabilitation centre (whose nutrition was presumably under medical control) revealed 32% of the patients had a body mass index (BMI) less than 20 kg/m<sup>2</sup>, 57% had diarrhoea and 24% steatorrhoea greater than 30 g/day.<sup>52</sup> Similarly, patients with CP awaiting elective surgery had a median BMI of 22 kg/m<sup>2</sup>.

A cross-sectional study of patients with alcoholic and idiopathic CP suggests that pancreatic exocrine insufficiency is considerably more widespread than is generally assumed. Using acid steatocrit and triolein breath tests, this study identified malabsorption in 72% of patients, of whom only around one-third complained of clinical steatorrhoea. Exocrine dysfunction was present in 63% of patients after 5 years of CP and 94% of those with disease lasting 10 years or more.<sup>53</sup> Around 10% of CP patients with exocrine insufficiency have no pain and their diagnosis derives from investigation of either diabetes or steatorrhoea.

In summary, these studies (summarised in Table 4) suggest that the prevalence of pancreatic exocrine insufficiency among patients with CP varies widely from low/moderate (11–20%) to very high (85–94%). It is reasonable to reckon that pancreatic exocrine insufficiency is a feature in 35–50% of patients 10 to 15 years after clinical onset, and generally increases thereafter. However, cross-sectional, especially hospital or gastroenterologist-based surveys, face the same difficulties in studying the epidemiology of pancreatic exocrine insufficiency as they do in estimating the prevalence of CP. Pancreatic exocrine insufficiency is predominantly a feature of late-stage CP, and most of these patients are invisible to hospital- and gastroenterologist-based surveys since they are treated in the community.

### Conclusion

Understanding of the epidemiology of CP has not improved in the last decade. The 2003 study by Lévy et al. found an incidence of 7.8/100,000. This implied a prevalence of 90,000 patients in France (120–143/100,000), assuming a life expectancy of 20 years from onset of CP. The authors consider that the prevalence



**Table 4.** Prevalence of pancreatic exocrine insufficiency in patients with chronic pancreatitis

Reference	Country	Study Type	Method of diagnosis	Patient population	Period	Pancreatic exocrine insufficiency
Lott, 1997 <sup>55</sup>	USA	Review			1958–1995	30% in mild and 85% in severe chronic pancreatitis
Dumasy et al., 2004 <sup>51</sup>	Belgium	Cross-sectional, hospital	Clinical steatorrhea	60 patients with pancreatitis 944 alcoholic, 16 idiopathic	NR	63% within 5 years, 94% after 10 years
Eddes et al., 1999 <sup>56</sup>	Netherlands	Cross-sectional, hospital	Clinical symptoms (weight loss, steatorrhea)	45 patients with chronic pancreatitis	NR	56%
Jarosz et al., 2003 <sup>57</sup>	Poland	Population-based	Clinical symptoms	389 patients with chronic pancreatitis	1982–2001	<5 years duration: 5.1% 3–10 years duration: 19.4% >10 years duration: 36.5%
Lévy et al., 2006 <sup>26</sup>	France	Cross-sectional study	Clinical signs (76.7%) Measurement of faecal pancreatic enzymes (5.8%) Faecal fat (27.1%)	1748 chronic pancreatitis patients identified in survey of gastroenterologists	4 months, 2003	Prevalence 36%
Frulloni et al., 2006 <sup>58</sup>	Italy	Prospective study	Not stated	834 patients with chronic pancreatitis	NR	Prevalence 31–45%

of the disease is probably underestimated for a variety of reasons, not least of these being the unreliability of alcohol-dependent patients in attending either hospital outpatient clinics or general practitioner facilities. More accurate incidence and prevalence data may in future be identified by greater utilisation of improved diagnostic approaches such as EUS. Coordination of data recording on CP patients by specialists in gastroenterology, diabetes, nutrition, surgery, psychiatry and general practice is needed to learn more about this disease in order to further medical knowledge.

### Funding

Assistance with the preparation of the manuscript was provided by Dr JF Stolz and funded by Abbott.

### Conflict of interest

P Levy has received honoraria and reimbursement grants for congress registration and travel from Solvay and Abbott and Mayoly Spindler on an irregular basis; M Lohr has received honoraria from Solvay and Abbott; E. Domínguez-Munoz has acted as advisor and speaker for Solvay and Abbott; C Imrie has received honoraria from Solvay and Abbott for consultancy and lecturing activities.

### Acknowledgements

This review is based on the proceedings of the Chronic Pancreatitis Epidemiology Expert Working Group that was convened by Abbott in 2011. The Expert Working Group comprised the authors of this manuscript.

### References

- Talamini G, Bassi C, Butturini G, et al. Outcome and quality of life in chronic pancreatitis. *JOP* 2001; 2: 117–123.
- Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. *N Engl J Med* 1993; 328: 1433–1437.
- Malka D, Hammel P, Sauvanet A, et al. Risk factors for diabetes mellitus in chronic pancreatitis. *Gastroenterology* 2000; 119: 1324–1332.
- Banks PA. Classification and diagnosis of chronic pancreatitis. *J Gastroenterol* 2007; 42(suppl.17): 148–151.
- Domínguez-Munoz JE. Diagnosis of chronic pancreatitis: Functional testing. *Best Pract Res Clin Gastroenterol* 2010; 24: 233–241.
- Choueiri NE, Balci NC, Alkaade S, et al. Advanced imaging of chronic pancreatitis. *Clin Gastroenterol Rep* 2010; 12: 114–120.
- Akisik MF, Sandrasegaran K, Jennings SG, et al. Diagnosis of chronic pancreatitis by using apparent diffusion coefficient measurements at 3.0-T MR following secretin stimulation. *Radiology* 2009; 252: 418–425.
- Balci C. MRI assessment of chronic pancreatitis. *Diagn Interv Radiol* 2010; 10: 1305–3825.

9. Buscail L, Escourrou J, Moreau J, et al. Endoscopic ultrasonography in chronic pancreatitis: A comparative prospective study with conventional ultrasonography, computed tomography, and ERCP. *Pancreas* 1995; 10: 215–217.
10. Sahai AV, Zimmerman M, Aabakken L, et al. Prospective assessment of the ability of endoscopic ultrasound to diagnose, exclude, or establish the severity of chronic pancreatitis found by endoscopic retrograde cholangiopancreatography. *Gastrointest Endosc* 1998; 48: 18–25.
11. Catalano MF, Lahotu S, Geenen JE, et al. Prospective evaluation of endoscopic ultrasonography, endoscopic retrograde pancreatography, and secretin test in the diagnosis of chronic pancreatitis. *Gastrointest Endosc* 1998; 48: 11–17.
12. Catalano MF, Sahai A, Levy M, et al. EUS-based criteria for the diagnosis of chronic pancreatitis: the Rosemont classification. *Gastrointest Endosc* 2009; 69: 1251–1261.
13. Wallace MB, Hawes RH, Durkalski V, et al. The reliability of EUS for the diagnosis of chronic pancreatitis: Interobserver agreement among experienced endosonographers. *Gastrointest Endosc* 2001; 53: 294–299.
14. Mössner J, Keim V, Niederau C, et al. Guidelines for therapy of chronic pancreatitis. Consensus Conference of the German Society of Digestive and Metabolic Diseases. Halle 21–23 November 1996. *Z Gastroenterol* 1998; 36: 359–367.
15. Bornman PC, Botha JF, Ramos JM, et al. Guideline for the diagnosis and treatment of chronic pancreatitis. *S Afr Med J* 2010; 100: 845–860.
16. Frulloni L, Falconi M, Gabbriellini A, et al. Italian consensus guidelines for chronic pancreatitis. *Dig Liver Dis* 2010; 42(Suppl 6): S381–S406.
17. Toouli J, Biankin AV, Oliver MR, et al. Management of pancreatic exocrine insufficiency: Australasian Pancreatic Club recommendations. *Med J Aust* 2010; 193: 461–467.
18. Żuk K, Czkwianianc E, Degowska M, et al. [Guidelines for diagnosis and treatment of chronic pancreatitis. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Pancreatic Club]. *Przegląd Gastroenterol* 2011; 6: 339–352.
19. Johnson CD and Hosking S. National statistics for diet, alcohol consumption, and chronic pancreatitis in England and Wales, 1960–88. *Gut* 1991; 32: 1401–1405.
20. Yadav D, Timmons L, Benson JT, et al. Incidence, prevalence, and survival of chronic pancreatitis: A population-based study. *Am J Gastroenterol* 2011; 106: 2192–2199.
21. Jaakkola M and Nordback I. Pancreatitis in Finland between 1970 and 1989. *Gut* 1993; 34: 1255–1260.
22. Andersen BN, Pedersen NT, Scheel J, et al. Incidence of alcoholic chronic pancreatitis in Copenhagen. *Scand J Gastroenterol* 1982; 17: 247–252.
23. Dzieniszewski J, Jarosz M and Ciok J. Chronic pancreatitis in Warsaw. *Mater Med Pol* 1990; 22: 202–204.
24. Lankisch PG, Assmus C, Maisonneuve P, et al. Epidemiology of pancreatic diseases in Luneburg county. A study in a defined German population. *Pancreatol* 2002; 2: 469–477.
25. Díte P, Starý K, Novotný I, et al. Incidence of chronic pancreatitis in the Czech Republic. *Eur J Gastroenterol Hepatol* 2001; 13: 749–750.
26. Lévy P, Barthet M, Mollard BR, et al. Estimation of the prevalence and incidence of chronic pancreatitis and its complications. *Gastroenterol Clin Biol* 2006; 30: 838–844.
27. Otsuki M. Chronic pancreatitis in Japan: Epidemiology, prognosis, diagnostic criteria, and future problems. *J Gastroenterol* 2003; 38: 315–326.
28. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Prognosis of chronic pancreatitis: An international multicenter study. International Pancreatitis Study Group. *Am J Gastroenterol* 1994; 89: 1467–1471.
29. Lowenfels AB and Maisonneuve P. Defining the role of smoking in chronic pancreatitis. *Clin Gastroenterol Hepatol* 2011; 9: 196–197.
30. Coté GA, Yadav D, Slivka A, et al. Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis. *Clin Gastroenterol Hepatol* 2011; 9: 266–273.
31. Andriulli A, Botteri E, Almasio PL, et al. Smoking as a cofactor for causation of chronic pancreatitis: A meta-analysis. *Pancreas* 2010; 39: 1205–1210.
32. Yadav D, Slivka A, Sherman S, et al. Smoking is under-recognized as a risk factor for chronic pancreatitis. *Pancreatol* 2010; 10: 713–719.
33. Wang LW, Li ZS, Li SD, et al. Prevalence and clinical features of chronic pancreatitis in China: A retrospective multicenter analysis over 10 years. *Pancreas* 2009; 38: 248–254.
34. European Commission. Report on Alcohol in Europe. [http://ec.europa.eu/health-eu/news\\_alcoholineurope\\_en.htm](http://ec.europa.eu/health-eu/news_alcoholineurope_en.htm) (accessed 16 March 2012).
35. Pedrazzoli S, Pasquali C, Guzzinati S, et al. Survival rates and cause of death in 174 patients with chronic pancreatitis. *J Gastrointest Surg* 2008; 12: 1930–1937.
36. Hirota M, Shimosegawa T, Masamune A, et al. The sixth nationwide epidemiological survey of chronic pancreatitis in Japan. *Pancreatol* 2012; 12: 79–84.
37. Ammann RW. Natural history of chronic pancreatitis. *Digest Surg* 1994; 11: 267–274.
38. Alexandre M, Pandol SJ, Gorelick FS, et al. The emerging role of smoking in the development of pancreatitis. *Pancreatol* 2011; 11: 469–474.
39. Ammann RW, Heitz PU and Klöppel G. Course of alcoholic chronic pancreatitis: A prospective clinicomorphological long-term study. *Gastroenterology* 1996; 111: 224–231.
40. Ammann RW, Akovbiantz A, Largadèr F, et al. Course and outcome of chronic pancreatitis: Longitudinal study of a mixed medical–surgical series of 245 patients. *Gastroenterology* 1984; 86: 820–828.
41. Cavallini G, Frulloni L, Pederzoli P, et al. Long-term follow-up of patients with chronic pancreatitis in Italy. *Scand J Gastroenterol* 1998; 33: 880–889.
42. Thuluvath PJ, Imperio D, Nair S, et al. Chronic pancreatitis. Long term pain relief with or without surgery, cancer risk, and mortality. *J Clin Gastroenterol* 2003; 36: 159–165.

43. Schnelldorfer T, Lewin DN and Adams DB. Operative management of chronic pancreatitis: Long term results in 372 patients. *J Am Coll Surg* 2007; 204: 1039–1045.
44. Seicean A, Tantau M, Grigorescu M, et al. Mortality risk factors in chronic pancreatitis. *J Gastrointest Liver Dis* 2006; 15: 21–26.
45. Levy P, Milan C, Pignon JP, et al. Mortality factors associated with chronic pancreatitis. Unidimensional and multidimensional analysis of a medical-surgical series of 240 patients. *Gastroenterology* 1989; 96: 1165–1172.
46. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ* 2004; 328: 1519.
47. INED. [http://www.ined.fr/en/pop\\_figures/france/deaths\\_causes\\_mortality/life\\_expectancy/](http://www.ined.fr/en/pop_figures/france/deaths_causes_mortality/life_expectancy/) (accessed 10 July 2011)
48. Domínguez-Muñoz JE, Iglesias-García J, Vilariño-Insua M, et al. <sup>13</sup>C-mixed triglyceride breath test to assess oral enzyme substitution therapy in patients with chronic pancreatitis. *Clin Gastroenterol Hepatol* 2007; 5: 484–488.
49. Lankisch PG, Schmidt I, König H, et al. Faecal elastase 1: Not helpful in diagnosing chronic pancreatitis associated with mild to moderate exocrine pancreatic insufficiency. *Gut* 1998; 42: 551–554.
50. Siegmund E, Löhr JM and Schuff-Werner P. [The diagnostic validity of non-invasive pancreatic function tests—a meta-analysis]. *Z Gastroenterol* 2004; 42: 1117–1128.
51. Dumasy V, Delhay M, Cotton F, et al. Fat malabsorption screening in chronic pancreatitis. *Am J Gastroenterol* 2004; 99: 1350–1354.
52. Armbrecht U. Chronic pancreatitis: Weight loss and poor physical performance – experience from a specialized rehabilitation centre. *Rehabilitation (Stuttg)* 2001; 40: 332–336.
53. Hammer HF. Pancreatic exocrine insufficiency: diagnostic evaluation and replacement therapy with pancreatic enzymes. *Dig Dis* 2010; 28: 339–343.
54. Garg PK and Tandon RK. Survey on chronic pancreatitis in the Asia-Pacific region. *J Gastroenterol Hepatol* 2004; 19: 998–1004.
55. Lott JA (ed). *Clinical Pathology of Pancreatic Disorders (Pathology and Laboratory Medicine)*. Totowa, NJ: Humana Press Inc.
56. Eddes EH, Masclee AA, Gielkens HA, et al. Cholecystokinin secretion in patients with chronic pancreatitis and after different types of pancreatic surgery. *Pancreas* 1999; 19: 119–125.
57. Jarosz M, Dzieniszewski J and Orzeszko M. 20-years prospective epidemiological-clinical observations of the chronic pancreatitis. *Gastroenterologia Polska* 2003; 10: 371–378.
58. Frulloni L, Gabbrielli A, Pezzilli R, et al; PanCroInfAISP Study Group. Chronic pancreatitis: Report from a multicenter Italian survey (PanCroInfAISP) on 893 patients. *Dig Liver Dis* 2009; 41: 311–317.